A CHALLENGE OF ENORMOUS SCALE AND URGENCY
50M
adults live with chronic pain, with few effective treatments available
1M+
adults in the US are living with Parkinson’s disease
~13M
people in the US are affected by PTSD each year
19M+
people provide unpaid care for loved ones with neuropsychiatric or neurodegenerative disorders
$193B+
in lost earnings each year due to mental health disorders & $800B+ in annual economic costs
Addressing critical CNS needs with next-generation therapies
Advances in biology, chemistry, and data science are redefining CNS drug discovery. Psy combines these innovations with proven expertise and a deep commitment to develop differentiated therapies with improved potential for clinical success.
Explore our approach
Team
Mission-driven team combines neuroscience, CNS drug development, and business-building expertise
Pipeline
Three lead small-molecule programs with strong profiles are approaching near-term, value-inflecting milestones
Approach
Leveraging known biology, innovative chemistry, and clear biomarkers to develop novel molecules